TrialAddiction (Abingdon, England)2022

Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.

Kara E Rudolph et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.